Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2928 in advanced cancers
NCT05192512Phase 1Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tqb2928 in solid tumor (advanced stage), hematological malignancies and lymphoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
tqb2928
03
Conditions
solid tumor (advanced stage)hematological malignancieslymphoma
Beyond the preview
Go deeper on NCT05192512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192512.